Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Anacor received rival...

    Anacor received rival bid before Pfizer deal

    Written by savita thakur thakur Published On 2016-05-30T16:52:12+05:30  |  Updated On 30 May 2016 4:52 PM IST
    Anacor received rival bid before Pfizer deal

    Anacor Pharmaceuticals Inc had received an offer from a third party before it agreed to be bought by Pfizer Inc in a $5.2 billion deal, regulatory filings showed.


    Pfizer agreed to buy Anacor on May 16 to add an eczema gel to its portfolio, a month after the U.S. drug major scrapped plans to acquire Allergan Plc.


    At the time, some analysts said they had expected Anacor to be acquired by Allergan, which has a stronger presence in the dermatology market, or by Novartis AG's Sandoz unit, which sells Anacor's toenail fungus drug in the United States.


    Anacor said in a regulatory filing on Thursday that Pfizer originally offered $95 per share on May 6 but its financial adviser, Citi, recommended the company improve the bid, given Anacor had received another offer.


    On May 13, Pfizer communicated to Citi its "best and final" offer of $99.25 per share, while the other bidder said it was ready to offer $90 per share, and an additional $500 million of crisaborole generated net sales of more than $1 billion in the first eight quarters post launch.


    Anacor's crisaborole is currently being reviewed by the U.S. Food and Drug Administration.


    Some analysts have also said the relatively low termination fee of about $181 million could persuade Anacor to accept a superior proposal.


    Anacor's shares ended the day up about 1 percent at $100.07 on Thursday. They had closed above Pfizer's offer price for eight of the nine days since May 16.

    Allergan PlcAnacor PharmaceuticalsNovartis AGPfizerSandoz
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok